Neem's Hill AB (publ), a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB (publ) in July 2026. The company was incorporated in 2013 and is headquartered in Lund, Sweden.…
Neem’s Hill (Q3 Initial take): Flat sales despite growing utilisation - Redeye
Neem's Hill (STO: NEEMS-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.000 SEK on 20 November 2026, down 47.5% over 52 weeks. Its 52-week range is 1.805 SEK to 5.480 SEK: the price is 63.5% below the high and 10.8% above the low.
Its market capitalisation is 52.43M SEK.
Neem's Hill reports return on equity of -252.9%, an operating margin of -54.5% and revenue up 1.6% year over year.
It holds more cash than debt, a net cash position of 1.92M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.700 SEK is 185.0% above the current price.
No upcoming events tracked.